Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Industry Valued at $2.51 Billion by 2029 With CAGR of 6% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market from 2024 to 2025?
Over the past few years, the market size for poly(ADP-ribose) polymerase (PARP) inhibitors has been expanding swiftly. This market, from its $6.53 billion size in 2024, is projected to develop to $7.56 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. Factors contributing to the growth in this historic period include higher instances of cancer, a surge in genetic testing, increased success rates in clinical trials, expanded insurance coverage, and advancements in cancer research.
What Is the Projected Market Size of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The market size of poly(ADP-ribose) polymerase (PARP) inhibitors is projected to experience a rapid surge in the coming years, reaching $13.45 billion by 2029 with a compound annual growth rate (CAGR) of 15.5%. The anticipated growth can be linked to several factors such as the escalated manufacturing and supply of drugs, increased incidence of BRCA-mutated cancers, growing cases of breast cancer, expanding use of monoclonal antibodies, and amplified healthcare spending. Key trends expected to emerge during the forecast period are progress in biomarker research, application of combination therapies, incorporation of artificial intelligence in drug discovery, advancements in biomarker-triggered therapy, and the creation of next-generation PARP inhibitors.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
Who are the Major Competitors in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Outlook?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
What Is Fueling Growth in the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The increased frequency of breast cancer is anticipated to drive the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a condition characterized by unrestricted cell growth in the breast, creating a malignant tumor that can metastasize to other bodily regions. The escalation in breast cancer cases is linked to factors such as aging populations, lifestyle modifications, genetic susceptibility, hormonal imbalances, obesity, alcohol intake, and heightened exposure to environmental hazards. PARP inhibitors assist breast cancer patients by impeding the repair of DNA damage in the cancer cells by the PARP enzyme, causing cell death, especially in tumors with BRCA1 or BRCA2 mutations. For example, the National Breast Cancer Foundation, a US-based entity, stated in January 2025 that one in every eight women in the USA will be diagnosed with breast cancer at some point in her life. In 2024, 310,720 women and 2,800 men received a diagnosis of invasive breast cancer. Consequently, the increasing incidence of breast cancer is spurring the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
Which Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segments Are Growing the Fastest?
The poly(ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –
1) By Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Types
2) By Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers, HRD-Positive Cancers, Maintenance Therapy
2) By Rucaparib: Ovarian Cancer, Prostate Cancer, Pancreatic Cancer
3) By Niraparib: First-Line Treatment, Recurrent Cancer Treatment, Late-Stage Cancer
4) By Talazoparib: Breast Cancer, Germline BRCA-Mutated Tumors, Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors, Investigational Therapies, Novel Combinations
Which Industry Trends Are Shaping the Future of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Leading businesses in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on advancing treatments for cancer, such as anticancer medications targeted at specific genetic mutations in certain types of cancer. These drugs, aimed at cancer treatment, work by hampering the proliferation of cancer cells, curbing their spread, or annihilating them. The drugs achieve this via different methods, such as interrupting cellular division, targeting specific proteins crucial for tumor development, or invigorating the immune system to counteract cancer. For example, Zydus Lifesciences Limited, based in India, introduced IBYRA, a generic form of the Parp inhibitor olaparib, in India in March 2024. This medication offers an economical and precise treatment option for those suffering from HRD-positive and BRCA-positive cancers, substantially lowering treatment expenses compared to the original drug.
Access The Full Report Here:
Which Countries Are Leading the Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102
This Report Delivers Insight On:
1. How big is the poly(adp-ribose) polymerase (parp) inhibitors market, and how is it changing globally?
2. Who are the major companies in the poly(adp-ribose) polymerase (parp) inhibitors market, and how are they performing?
3. What are the key opportunities and risks in the poly(adp-ribose) polymerase (parp) inhibitors market right now?
4. Which products or customer segments are growing the most in the poly(adp-ribose) polymerase (parp) inhibitors market?
5. What factors are helping or slowing down the growth of the poly(adp-ribose) polymerase (parp) inhibitors market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
